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Abstract
Background. The most common site of colorectal extra-abdominal metastases is the lung. The relative risk of lung
metastases after resection and cryotherapy has not previously been compared. Methods. All patients underwent an extensive
preoperative staging including clinical examination, abdominal computed tomography (CT) and abdominal angio-CT
to assess their hepatic disease. Two groups of patients were compared in this study (hepatic resection alone and
hepatic cryotherapy with or without resection). A retrospective analysis of prospectively collected data was performed to
assess the incidence and disease-free interval of pulmonary metastasis after surgical treatment of colorectal liver
metastasis. Results. This paper clearly shows two differences regarding pulmonary metastases between patients treated
with resection only and cryotherapy with or without resection. Among the 10 clinical variables, cryotherapy had the greatest
correlation with pulmonary metastases (p/0.004). A patient who undergoes hepatic resection only has a probability of 35%
for developing pulmonary recurrence, compared with 51% following cryotherapy. Cryotherapy was also independently
associated with shorter pulmonary disease-free interval (p/0.036). Conclusion. There clearly is a higher risk of pulmonary
metastasis after cryotherapy than after resection, whether this is related to selection of patients or a direct deleterious
procedural effect requires more study.
Introduction
Colorectal cancer is a major cause of cancer-related
mortality; 40% of these patients will develop hepatic
metastases [1]. Liver resection has been regarded as
the only curative treatment for colorectal liver metas-
tases, yielding 5-year survival of 20/30% [2/4].
However, only 25% of such patients are suitable for
liver resection, due to extensive hepatic disease, extra-
hepatic spread at presentation or the patients poor
performance status [5/7].
Hepatic cryotherapy was the first widely used
ablative technique [5] for colorectal liver metastases
and is a relatively safe and effective alternative
treatment for colorectal liver metastases, achieving
a 5-year survival of 20% [8]. We have also used the
combined treatment modality of liver resection and
cryotherapy for residual disease in the contralateral
lobe (contralobe cryotherapy) and this has produced
similar survival results to hepatic resection alone
[9,10]. Edge-cryotherapy for close margins appears
to substantially reduce the risk of recurrence and
achieves 20% 5-year survival even in patients with
involved margins [11]. These surgical techniques
and others allow us to offer potentially curative
surgery to a greater proportion of patients with
liver-only disease and the survival is much superior
to that achieved with regional or systemic che-
motherapy.
The most common site of colorectal extra-ab-
dominal metastases is the lung. The risk of lung
metastases after resection and cryotherapy has not
previously been reported. These procedures have
fundamental differences. We hypothesized that a
higher pulmonary recurrence rate after hepatic
cryotherapy might be seen as a result of intravas-
cular dissemination due to detachment of viable
tumour emboli during cryo-probe introduction and
after thawing. We also hypothesized that the greater
cytokine release following cryotherapy could up-
regulate the expression of adhesion molecules in
vascular endothelium, thus favouring tumour cell
implantation and growth of metastases. The aim of
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this study was to compare the incidence of pul-
monary metastases after hepatic resection with that
after hepatic cryotherapy.
Materials and methods
Patient selection
Between April 1990 and January 2003, 906 patients
had a laparotomy with the intention of surgical
treatment of colorectal liver metastases in our
institution. In all, 430 patients underwent hepatic
arterial catheter insertion for regional chemotherapy
only; 78 patients had cryotherapy applied to the
liver resection edge due to an involved or inade-
quate resection margin; 47 patients had cryotherapy
and/or resection with palliative intent because of the
presence of extrahepatic disease or extensive intra-
hepatic disease, which was not detected during
preoperative work-up; 53 patients had other types
of ablative or palliative surgical therapy including
radiofrequency ablation. The remaining 298 patients
underwent surgical treatment with curative intent
and formed the basis of this report. Among them,
160 patients had liver resection, 74 patients had
combined treatment of resection and contralobe
cryotherapy and 64 had cryotherapy alone. Patients
were considered for liver resection on the basis of
the following criteria: (1) absence of extrahepatic
disease; (2) preservation of adequate functional liver
tissue. Patients were considered for cryotherapy
alone or in combination with resection on the basis
of the following criteria: (1) absence of extrahepatic
disease; (2) bilobar liver disease beyond the reach of
resection to achieve total clearance in which
cryotherapy allowed focal destruction of tumours
and preservation of functional liver tissue (Note that
the number of colorectal liver metastases per se was
not a criterion for deciding whether the patient
would receive resection, cryotherapy or both, be-
cause the authors believe that number is not a
strong prognostic determinant for survival [8]).
Preoperative management
All of these patients underwent an extensive
preoperative work-up including clinical examination,
abdominal computed tomography (CT), chest CT,
pelvic CT and bone scan to exclude extrahepatic
disease. Positron emission tomography (PET) was not
routinely available. If liver resection or cryotherapy
was indicated, abdominal angio-CT was used for
assessment of hepatic involvement (number, size and
localization) and resectability. Measurements of liver
function and preoperative carcinoembryonic antigen
(CEA) level were carried out. A preoperative biopsy of
the hepatic tumour was not usually performed.
Operative technique
The initial right subcostal incision was performed to
exclude extrahepatic malignancy. Any suspicious
lymph node or peritoneal nodule was biopsied for
frozen section histology. A thorough examination of
the liver was performed both by palpation and by
intraoperative ultrasonography (IOUS) to confirm the
number, size, location (in relation to hepatic and
portal veins) and echogenicity of the tumours. When
liver resection or cryotherapy was feasible, the incision
was extended to bilateral subcostal or triradiate
incision and the liver was fully mobilized.
Liver resection was performed using an ultrasonic
dissector (Sumisonic ME-2210; Sumitomo Bakelite
Co., Japan or Selector Spembly UK), with portal
inflow occlusion only in selected cases to minimize
blood loss or improve the efficiency of cryotherapy.
Resection was used preferentially for large tumours,
because of high recurrence rates with cryotherapy
[12] and the relationship of cryo-volume to cryo-
shock [13].
Cryotherapy was performed using the LCS 3000
liquid nitrogen system (Spembly, Andover, UK) or
the Erbe system (Tubingen, Germany). For the
superficial lesions, a spike probe was inserted into
the centre of the lesion under direct vision. For the
deep intra-parenchymal lesions, a Seldinger-type
technique was used by placing an ultrasound (US)-
guided spinal needle in the tumour, followed by
insertion of cryo-probe(s) [5]. Intraoperative US
(IOUS) was used to monitor ice-ball formation and
in particular its extension beyond the tumour in all
planes by a margin of 1 cm [14,15]. In most cases, we
allow thawing of the outer rim of the ice-ball by
approximately 1 cm prior to refreezing (partial double
freeze-thaw cycle) to increase the lethality of freezing,
because complete thawing would considerably in-
crease the operative time and, more importantly,
complete thawing and refreezing is causally associated
with the cryo-shock phenomenon [5,14,16,17], After
thawing, the probe was withdrawn gently and
some gelfoam was packed in the cryoprobe track to
minimize bleeding. Cryolesions often crack and any
subsequent bleeding was easily managed by suturing.
Hepatic arterial catheter insertions were routinely
placed and details of the technique are described
elsewhere [18,19].
Postoperative management
Adjuvant hepatic arterial chemotherapy with 1 g
5-fluorouracil per 24 hours for 4 days every 2 weeks,
was commenced within 1 month of the cryosurgery.
Patients were reviewed 1 month after their surgery
and at 3-monthly intervals thereafter. This included
clinical examination and measurement of CEA level.
Any rise in CEA levels was investigated by CT to
identify recurrent disease. In patients with a serum
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CEA level of B/5 ng/ml preoperatively (non-CEA
secretors) abdominal CT was performed every
3 months. All patients were followed up until January
2004 or until death occurred. A minority of patients
who were privately insured received 5-fluorodeoxy-
uridine (FUDR) rather than 5-FU. If FUDR was
to be used, we would recommend waiting at least
1 month before starting the therapy, otherwise bilo-
mas are likely to develop in the cryo-site(s) [20].
FUDR was given at 0.18 mg/kg for 2 weeks on and
2 weeks off. Systemic chemotherapy was only given to
the patients who developed extrahepatic metastases.
Statistical analysis
The study outcome of presence or absence of pul-
monary metastases was analysed by treatment groups
and available clinical factors. For univariate analysis,
x2 (or Fisher’s exact) test was used for categorical
factors, Wilcoxon rank test was used for the compar-
ison of difference in means of continuous factors.
Logistic regression was used for the multivariate
analysis of study outcome. All combinations of the
selected clinical variables were compared in order to
obtain the best prediction of outcome. The disease-
free survival analysis was performed using Kaplan-
Meier method and the log-rank test was used for the
comparison of survival between groups. Multivariate
analysis for disease-free interval was performed using
a Cox regression (Cox proportional hazards model)
with forward stepwise selection of covariates and with
enter and remove limits of pB/0.05 and p/0.10,
respectively. These statistical analyses were performed
using SPSS for Windows (Version 11.5; SPSS GmbH,
Munich, Germany). A significant difference was
assumed for p values B/0.05.
Results
Between April 1990 and January 2003, 298 patients
with colorectal hepatic metastases underwent surgical
treatment with curative intent in our liver unit. The
minimum length of follow-up was 12 months. One
hundred and sixty patients had hepatic resection
alone; 74 patients had resection and contralobe
cryotherapy and 64 patients had cryotherapy only.
One hundred and forty-one patients (47%) remained
alive. The overall median follow-up was 26 months
(range 12/110 months). The median follow-up was
26 months (range 12/85) in the resection group and
26 months (range 12/110) in the cryotherapy with or
without resection group. The mean length of follow-
up was 28 and 31 months for the resection and
cryotherapy groups, respectively. One hundred and
twenty-seven patients (43%) had developed pulmon-
ary recurrence at the last time of contact. The
distribution of nine clinical variables among these
two groups is shown in Table I and analysed using x2
test or Wilcoxon rank test. It showed that Interna-
tional Union Against Cancer TNM staging of the
primary tumor (p/0.001), synchronous vs metachro-
nous (p/0.000), number (p/0.000) and size (p/
0.000) of colorectal liver metastases were statistically
different between the two groups.
Mortality and morbidity rates
One patient (0.3%) died of myocardial infarction in
the hospital within 30 days postoperatively. Intrao-
perative haemorrhage that required transfusion of
more than four units of packed red blood cells
occurred in 18 patients (11%) in the resection group
and in 7 patients (5%) in the cryotherapy with or
without resection group. The total postoperative
morbidity rate was 29% (87 of 298 patients). Post-
operative complications included wound infection
(n/21), intra-abdominal abscess (n/26), adhesional
bowel obstruction (n/5), biloma or fistula (n/16),
bile leak (n/6), sclerosing cholangitis (n/7), re-
spiratory complications (n/28), cardiac complica-
tions (n/6) and renal complications (n/13).
Survival
The median survival was 38 months in the resection
group vs 32 months in the cryotherapy9/resection
group. The 1-, 3- and 5-year survivals were 87%, 51%
and 35% in the resection group vs 91%, 46% and
22% in the cryotherapy9/resection group, respectively
(Figure 1).
Incidence of colorectal pulmonary metastases
The correlation of clinical factors and incidence of
pulmonary metastases in 298 patients with surgically
treated colorectal liver metastases is indicated in
Table II. Statistical analysis was performed using x2
test and Wilcoxon rank test. Univariate analysis
showed that the only clinical factor that was indepen-
dently associated with a higher incidence of pulmon-
ary metastases was the use of cryotherapy with or
without resection (p/0.004). Logistic regression
showed that operation type (resection vs cryotherapy
with or without resection) had the greatest magnitude
of odds ratio of outcome. Number of lesions and other
factors were not associated with development of lung
metastasis. A patient who underwent hepatic resec-
tion only had a probability of 35% of developing
pulmonary recurrence, compared with 51% if they
had cryotherapy. The incidence of concurrent meta-
static disease with pulmonary metastases is demon-
strated in Table III.
Disease-free interval (DFI) of colorectal pulmonary
metastases
Ten clinical factors in Table II were entered into the
Cox regression model (Table IV). It demonstrated
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that low preoperative CEA level (5/5.0 ng/ml) (p/
0.005) and the use of resection alone (p/0.036) were
independently associated with longer disease-free
interval in-the lung. Figure 2 showed the difference
in time until recurrence of pulmonary metastases
following resection only vs cryotherapy with or with-
out resection for colorectal liver metastases, calcu-
lated by Kaplan-Meier analysis.
Discussion
Cryotherapy alone or in combination with resection
has been increasingly recognized as an effective local
treatment modality for non-resectable colorectal liver
metastases. It has increased the scope of patients to
receive a potentially curative therapy, achieving a
median survival of more than 2 years in most
published series and is associated with 5-year survival
in approximately one-fifth of patients [5]. The most
common site of extra-abdominal metastases from
colorectal carcinoma is the lung and the incidence of
this following hepatic resection vs cryotherapy has not
been reported previously. This paper clearly shows
two most important differences regarding pulmonary
metastases between patients treated with resection
only and cryotherapy with or without resection.
Firstly, among the 10 clinical variables (Table I),
cryotherapy with or without resection demonstrates
the greatest correlation with pulmonary metastases.
Secondly cryotherapy with or without resection is
independently associated with shorter pulmonary
disease-free interval.
The resection group is associated with fewer, but
larger tumour nodules and more metachronous
disease than the cryotherapy group. We acknowl-
edge that even though these variables were not
found to be significant in either the univariate or
the multivariate analyses for the risk of developing
pulmonary metastases (Tables II and IV), it is still
possible that these discrepancies were due to a
difference in the known prognostic features of the
two groups.
Table I. The distribution of nine clinical variables in the resection only group and the cryotherapy with or without resection group (n/
298).
Parameter Resection only Cryotherapy9/resection
Clinical factors n/160 % n/138 % p value
Gender 0.581
Male 90 56 82 59
Female 70 44 56 41
Age (years) 0.165
5/60 66 41 68 49
/60 94 59 70 51
UICC TNM staging 0.001
Stage I and II 53 33 25 18
Stage III 55 34 37 27
Stage IV 37 23 60 44
Unknown 15 9 16 11
Primary histological differentiation 0.439
Well/moderate 115 72 95 69
Poor 20 12 14 10
Unknown 25 16 29 21
Treatment time of liver metastases 0.000
Synchronous 15 9 60 43
Metachronous 145 91 78 57
No. of liver metastases 0.000
1 91 57 12 9 0.000*
2/3 55 34 53 38
/3 14 9 73 53
Largest size of liver metastases 0.000
1/3 cm 42 26 91 66 0.000*
4/6 cm 55 34 34 25
/7 cm 63 40 13 9
Preoperative CEA level (ng/ml) 0.164
5/5.0 43 27 34 24
5.01/100.0 81 51 59 43
/100.0 22 14 22 16
Unknown 14 9 23 17
Postoperative CEA level (ng/ml) 0.840
5/5.0 121 76 104 75
/5.0 25 15 24 17
Unknown 14 9 10 7
* Analysed using Wilcoxon rank test.
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We think that technique-related failure should be
considered. For any haematogenous or lymphatic
metastasis to occur, firstly tumour cells have to be
released into the circulation or interstitial tissues,
respectively. During hepatic cryotherapy, introducing
a large cryo-probe into tumours might physically
dislodge tumour cells into the systemic circulation.
Bleeding from the probe introduction point is often
seen and a communication of dislodged tumour cells
and the vascular space is clearly present. This is in
contrast to a resection, where en bloc removal of
tumour is performed. It is also thought that tumour
cells are held together by intercellular adhesion
molecules [21]. Cryotherapy-induced cell necrosis
may destroy the basement membrane and micro-
vascular endothelium and may also interfere with
the cell to cell adhesion, hence some viable tumour
cells, especially at the periphery of the ice-ball, may
release themselves and enter the circulation. Once
tumour cells enter the systemic circulation, they are
most likely to be entrapped in the microvasculature of
the lung and may be related to why the lung is the
most frequent site of haematogenous metastasis.
However, subsequent endothelial adhesion, inva-
sion and basement membrane penetration have to
occur, in order for pulmonary metastasis to develop
[22]. We know that during an inflammatory response,
cytokines serve important roles in chemotaxis
and adhesion between leukocytes and endothelium.
Various cytokines are produced by leukocytes and
lymphocytes and endothelial cells, such as tumour
necrosis factor (TNF), interleukin (IL)-1 and inter-
feron-gamma (IFN-gamma). These cytokines
up-regulate the expression of various adhesion mole-
cules, such as the endothelial leukocyte adhesion
molecule-1 (ELAM-1), vascular cell adhesion mole-
cule-1 (VCAM-1) or the intercellular adhesion
molecule-1 (ICAM-1) [23], which in turn facilitate
white cells to adhere to the activated endothelial cells,
migrate through the vessel wall, and penetrate areas
of infection or tissue damage. Tumour cell interaction
with endothelium and subendothelial matrix
constitutes a crucial factor in metastasis, and the
adhesion of tumour cells to the endothelium might
share the same mechanism as that in inflammation
[24,25]. Many studies have demonstrated that cyto-
kines increase the adhesion of tumour cells in vitro
[26/29]. Dejana et al . [28] showed that IL-1 pro-
motes tumour cell adhesion to cultured human
endothelial cells and Giavazzi et al . [30] demonstrated
that IL-1 enhanced human melanoma metastasis in
nude mice. Yanase et al . [31] concluded that TNF,
IL-1 and particularly IL-6 augmented expression of
VCAM-1 on endothelium, _which resulted in en-
hancement of adhesion between endothelium and
renal cell carcinoma cells.
It is known that cryotherapy induces cytokine
release, which is implicated in acute lung inflamma-
tion and the cryo-shock phenomenon [5]. Seifert et al .
[32] demonstrated that cryotherapy resulted in in-
creasing TNF-a and IL-6 release in both human and a
rat model. The exact mechanism(s) of increased
cytokine release is less clear and it may be related to
the thawing phase of cryotherapy, which results in
Figure 1. Survival in patients with colorectal liver metastases treated with resection only (solid line, n/160) and cryotherapy with or
without resection (dashed line, n/138) (p/0.076).
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plasma membrane disruption and dispersion of intact
cellular structures into the systemic circulation, which
in turn induce an inflammatory response [33]. It is
plausible to suggest that cryotherapy-induced cyto-
kine release may up-regulate endothelial adhesion
molecules as well, which in turn facilitate tumour
cell attachment to the pulmonary endothelium.
In fact, both tumour-suppressing and tumour-
enhancing effects were documented after cryotherapy
in several animal models without specific data depict-
Table III. The incidence of concurrent metastatic disease with pulmonary recurrence.
Resection only Cryotherapy9/resection
Overall pulmonary recurrence n/56 % n/71 %
Lung only 20 36 22 31
Lung and liver 25 45 39 55
Lung and other extrahepatic sites 7 12 2 3
Lung, liver and other extrahepatic sites 4 7 8 11
Lung and subsequently liver recurrence 15 27 29 41
Lung and subsequently other extrahepatic sites 8 14 8 11
Table II. The correlation of clinical factors and incidence of pulmonary metastases in 298 patients with surgically treated colorectal liver
metastases.
Factors Pulmonary recurrence
Yes No
Clinical factors n/127 % n/171 % p value
Gender 0.434
Male 70 55 102 60
Female 57 45 69 40
Age (years) 0.165
B/60 63 50 71 42
5/60 64 50 100 56
UICC TNM staging 0.305
Stage I and II 29 23 49 29
Stage III 44 35 48 28
Stage IV 44 35 53 31
Unknown 10 8 21 12
Primary histological differentiation 0.752
Well/moderate 89 70 121 71
Poor 13 10 21 12
Unknown 25 20 29 17
Treatment time of liver metastases 0.582
Synchronous 34 27 41 24
Metachronous 93 73 130 76
No. of liver metastases 0.300
1 42 33 61 36 0.140*
2/3 42 33 66 39
/3 43 34 44 25
Largest size of liver metastases 0.427
1/3 cm 53 42 80 47 0.656*
4/6 cm 43 33 46 27
/7 cm 31 24 45 26
Preoperative CEA level (ng/ml) 0.081
5/5.0 24 19 53 31
5.01/100.0 62 49 78 46
/100.0 21 16 23 13
Unknown 20 16 17 10
Postoperative CEA level (ng/ml) 0.201
5/5.0 95 75 130 76
/5.0 25 20 24 14
Unknown 7 5 17 10
Operation type 0.004
Resection only 56 44 104 61
Cryotherapy9/resection 71 56 67 39
* Analysed using Wilcoxon rank test.
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ing the underlying mechanism. Shibata et al . [34]
concluded that cryotherapy enhanced the growth of
tumour metastases compared with surgical excision in
rats. Joosten et al . [35] reported that cryotherapy of
tumour implantation in mice resulted in inhibition of
secondary and metastatic tumour growth in the lung,
as compared with resection, and suggested that a
cytokine response induced by cryoablation of tumour
tissue might be attributed to this finding. El-Shakhs et
al . [36] also failed to demonstrate that hepatic
cryotherapy enhances tumour dissemination in a rat
model. The different findings might be related to the
difference in their study designs. However, in all
studies, the immune-modulating effects of cryother-
apy on tumour activity were suggested, as cryotherapy
is associated with greater cytokine release than resec-
tion and other ablative techniques, such as radio-
frequency ablation (RFA).
Indeed, RFA has not been shown to be related to
large cytokine production and lung inflammation
[33]. It will be of great interest to see if lung metastasis
rates following RFA are different from cryotherapy;
however, the data in our study suggest that the
inhibition of cytokine release, or the blocking of their
effect, may be of broad value in cancer surgery to
reduce the risk of systemic metastasis.
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